Inflammatory Neuropathies

ABSTRACT

Inflammatory neuropathies are acquired disorders of peripheral nerves and occasionally of the central nervous system that can affect individuals at any age. The course can be monophasic, relapsing, or progressive. Inflammatory neuropathies are classified as acute or chronic. The acute form reaches a nadir by 4 weeks and the chronic form over 8 weeks or greater. The most common example of an acute inflammatory neuropathy is acute inflammatory demyelinating polyradiculoneuropathy (AIDP), which is part of the Guillain-Barré syndrome (GBS). The most common chronic inflammatory neuropathy is chronic inflammatory demyelinating polyradiculopathy (CIDP). Other chronic inflammatory neuropathies are multifocal motor neuropathy (MMN) and the Lewis-Sumner syndrome. The Fisher syndrome and Bickerstaff brainstem encephalitis occur acutely and have clinical overlap with AIDP.

KEYWORDS

Guillain-Barré syndrome - acute inflammatory demyelinating polyradiculoneuropathy - chronic inflammatory demyelinating polyradiculopathy - multifocal motor neuropathy - Lewis-Sumner syndrome

REFERENCES

• 1 Hughes R A, Rees J H. Clinical and epidemiologic features of Guillain-Barré syndrome.  J Infect Dis. 1997;  176(Suppl 2) S92-S98
• 2 G. Guillain JBaAS . Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellilaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux.  Bull Soc Med Hop Paris. 1916;  1462-1470
• 3 Ropper AHWE, Truax B Guillain-Barre Syndrome. Philadelphia, PA; FA Davis Company 1991
• 4 Winer J B, Hughes R A, Anderson M J, Jones D M, Kangro H, Watkins R P. A prospective study of acute idiopathic neuropathy. II. Antecedent events.  J Neurol Neurosurg Psychiatry. 1988;  51(5) 613-618
• 5 Moulin D E, Hagen N, Feasby T E, Amireh R, Hahn A. Pain in Guillain-Barré syndrome.  Neurology. 1997;  48(2) 328-331
• 6 Hadden R D, Karch H, Hartung H P Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.  Neurology. 2001;  56(6) 758-765
• 7 Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome.  Drug Saf. 2009;  32(4) 309-323
• 8 Hafer-Macko C E, Sheikh K A, Li C Y et al.. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy.  Ann Neurol. 1996;  39(5) 625-635
• 9 Albers J W, Kelly Jr J J. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features.  Muscle Nerve. 1989;  12(6) 435-451
• 10 Van den Bergh P Y, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy.  Muscle Nerve. 2004;  29(4) 565-574
• 11 Gordon P H, Wilbourn A J. Early electrodiagnostic findings in Guillain-Barré syndrome.  Arch Neurol. 2001;  58(6) 913-917
• 12 Albers J W, Donofrio P D, McGonagle T K. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy.  Muscle Nerve. 1985;  8(6) 528-539
• 13 Miller R G, Peterson G W, Daube J R, Albers J W. Prognostic value of electrodiagnosis in Guillain-Barré syndrome.  Muscle Nerve. 1988;  11(7) 769-774
• 14 Gorson K C, Ropper A H, Muriello M A, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome.  Neurology. 1996;  47(3) 813-817
• 15 McKhann G M, Griffin J W, Cornblath D R, Mellits E D, Fisher R S, Quaskey S A. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis.  Ann Neurol. 1988;  23(4) 347-353
• 16 Cornblath D R, Mellits E D, Griffin J W et al.. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value.  Ann Neurol. 1988;  23(4) 354-359
• 17 Bernsen R A, de Jager A E, Schmitz P I, van der Meché F G. Long-term impact on work and private life after Guillain-Barré syndrome.  J Neurol Sci. 2002;  201(1-2) 13-17
• 18 Feasby T E, Gilbert J J, Brown W F et al.. An acute axonal form of Guillain-Barré polyneuropathy.  Brain. 1986;  109(Pt 6) 1115-1126
• 19 Griffin J W, Li C Y, Ho T W et al.. Pathology of the motor-sensory axonal Guillain-Barré syndrome.  Ann Neurol. 1996;  39(1) 17-28
• 20 Hughes R A, Cornblath D R. Guillain-Barré syndrome.  Lancet. 2005;  366(9497) 1653-1666
• 21 Chaudhry V, Corse A M, Cornblath D R, Kuncl R W, Freimer M L, Griffin J W. Multifocal motor neuropathy: electrodiagnostic features.  Muscle Nerve. 1994;  17(2) 198-205
• 22 Ang C W, Jacobs B C, Laman J D. The Guillain-Barré syndrome: a true case of molecular mimicry.  Trends Immunol. 2004;  25(2) 61-66
• 23 Yuki N, Taki T, Takahashi M et al.. Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1 a epitope.  Infect Immun. 1994;  62(5) 2101-2103
• 24 Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia).  N Engl J Med. 1956;  255(2) 57-65
• 25 Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller-Fisher syndrome.  Neurology. 2001;  56(8) 1104-1106
• 26 Ilyas A A, Cook S D, Mithen F A et al.. Antibodies to GT1a ganglioside in patients with Guillain-Barré syndrome.  J Neuroimmunol. 1998;  82(2) 160-167
• 27 Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller-Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies.  Neurology. 1993;  43(10) 1911-1917
• 28 Liu J X, Willison H J, Pedrosa-Domellöf F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles.  Invest Ophthalmol Vis Sci. 2009;  50(7) 3226-3232
• 29 Kornberg A J, Pestronk A, Blume G M, Lopate G, Yue J, Hahn A. Selective staining of the cerebellar molecular layer by serum IgG in Miller-Fisher and related syndromes.  Neurology. 1996;  47(5) 1317-1320
• 30 Jamal G A, MacLeod W N. Electrophysiologic studies in Miller-Fisher syndrome.  Neurology. 1984;  34(5) 685-688
• 31 Katsuno M, Ando T, Hakusui S, Yanagi T, Sobue G. Motor conduction studies in Miller-Fisher syndrome with severe tetraparesis.  Muscle Nerve. 2002;  25(3) 378-382
• 32 Bickerstaff E R. Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis.  BMJ. 1957;  1(5032) 1384-1387
• 33 Bickerstaff E R, Cloake P C. Mesencephalitis and rhombencephalitis.  BMJ. 1951;  2(4723) 77-81
• 34 Mondéjar R R, Santos J M, Villalba E F. MRI findings in a remitting-relapsing case of Bickerstaff encephalitis.  Neuroradiology. 2002;  44(5) 411-414
• 35 Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome).  J Neuroimmunol. 2009;  215(1-2) 1-9
• 36 Austin J H. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone.  Brain. 1958;  81(2) 157-192
• 37 Dyck P J, Lais A C, Ohta M, Bastron J A, Okazaki H, Groover R V. Chronic inflammatory polyradiculoneuropathy.  Mayo Clin Proc. 1975;  50(11) 621-637
• 38 Gorson K. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Daube JR, Dillingham TR, Bromberg MB, Werner RA Proceedings of the 56th Annual AANEM. San Diego, CA; American Association of Neuromuscular & Electrodiagnostic Medicine 2009: 1-13
• 39 Koski C L, Baumgarten M, Magder L S et al.. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy.  J Neurol Sci. 2009;  277(1-2) 1-8
• 40 Dionne A, Nicolle M W, Hahn A F. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy.  Muscle Nerve. 2010;  41(2) 202-217
• 41 Benatar M Neuromuscular Disease: Evidence and Analysis in Clinical Neurology. Totowa, NJ; Humana Press 2006
• 42 Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force.  Neurology. 1991;  41 617-618
• 43 Bladé J. Clinical practice. Monoclonal gammopathy of undetermined significance.  N Engl J Med. 2006;  355(26) 2765-2770
• 44 Yan W X, Taylor J, Andrias-Kauba S, Pollard J D. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients.  Ann Neurol. 2000;  47(6) 765-775
• 45 Meléndez-Vásquez C, Redford J, Choudhary P P et al.. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy.  J Neuroimmunol. 1997;  73(1-2) 124-134
• 46 Gorson K C, Allam G, Ropper A H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy.  Neurology. 1997;  48(2) 321-328
• 47 Kuwabara S, Misawa S, Mori M, Tamura N, Kubota M, Hattori T. Long-term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases.  J Neurol Neurosurg Psychiatry. 2006;  77(1) 66-70
• 48 Parry G J, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease.  Muscle Nerve. 1988;  11(2) 103-107
• 49 Pestronk A, Cornblath D R, Ilyas A A et al.. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.  Ann Neurol. 1988;  24(1) 73-78
• 50 Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment.  Neurology. 2007;  69(17) 1680-1687
• 51 Bouche P, Moulonguet A, Younes-Chennoufi A B et al.. Multifocal motor neuropathy with conduction block: a study of 24 patients.  J Neurol Neurosurg Psychiatry. 1995;  59(1) 38-44
• 52 Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies.  Muscle Nerve. 2005;  31(6) 663-680
• 53 Van Asseldonk J T, Franssen H, Van den Berg-Vos R M, Wokke J H, Van den Berg L H. Multifocal motor neuropathy.  Lancet Neurol. 2005;  4(5) 309-319
• 54 Lambrecq V, Krim E, Rouanet-Larrivière M, Lagueny A. Sensory loss in multifocal motor neuropathy: a clinical and electrophysiological study.  Muscle Nerve. 2009;  39(2) 131-136
• 55 Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates.  Neurology. 1997;  49(5) 1289-1292
• 56 Beekman R, van den Berg L H, Franssen H, Visser L H, van Asseldonk J T, Wokke J H. Ultrasonography shows extensive nerve enlargements in multifocal motor neuropathy.  Neurology. 2005;  65(2) 305-307
• 57 Nobile-Orazio E. Multifocal motor neuropathy.  J Neuroimmunol. 2001;  115(1-2) 4-18
• 58 Van den Berg-Vos R M, Franssen H, Wokke J H, Van Es H W, Van den Berg L H. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment.  Ann Neurol. 2000;  48(6) 919-926
• 59 Vucic S, Black K R, Chong P S, Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg.  Neurology. 2004;  63(7) 1264-1269
• 60 Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile-Orazio E. How long is IVIg effective in multifocal motor neuropathy?.  Neurology. 2004;  62(4) 666-668
• 61 Lewis R A, Sumner A J, Brown M J, Asbury A K. Multifocal demyelinating neuropathy with persistent conduction block.  Neurology. 1982;  32(9) 958-964
• 62 Saperstein D S, Amato A A, Wolfe G I et al.. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome.  Muscle Nerve. 1999;  22(5) 560-566
• 63 Viala K, Renié L, Maisonobe T et al.. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome.  Brain. 2004;  127(Pt 9) 2010-2017
• 64 Lewis R A. Multifocal dysimmune demyelination neuropathies. In: AANEM 2009 Courses A&B, ed. San Diego, CA; American Association of Neuromuscular & Electrodiagnostic Medicine 2009: 35-43